Abstract 1735
Background
The previous analysis of phase 2, ASCEND-3 study (NCT01685138; data cutoff: November 15, 2015) demonstrated prolonged median progression-free survival (mPFS) with ceritinib 750 mg/d (fasted) in ALKi-naïve patients with ALK+ NSCLC, who had received ≤3 prior lines of chemotherapy. The current analysis (data cutoff: January 22, 2018) from ASCEND-3 study reports the final safety and efficacy results including overall survival (OS).
Methods
ASCEND-3 is a multicenter, single-arm, open-label, phase 2 study in ALKi-naïve patients (aged, ≥18 years) with locally advanced or metastatic ALK+ NSCLC, who had received ≤3 lines of chemotherapy. Patients received oral ceritinib 750 mg/d (fasted). Primary endpoint was overall response rate (ORR) per RECIST v1.1 (by investigator). Secondary endpoints were ORR (by blinded independent review committee [BIRC]); overall intracranial response rate (OIRR), duration of response (DOR), disease control rate (DCR), PFS (by investigator and BIRC); OS; and safety.
Results
Of 124 ceritinib-treated patients, 123 (99.2%) had received prior antineoplastic regimens (31 patients [25.0%], ≥3 regimens), and 49 (39.5%) had baseline brain metastases. Median follow-up time was 52.14 months (range, 48.4-60.1). Median duration of drug exposure was 23.2 months (range, 0.1-55.2). Median OS was 51.3 months (95% CI: 42.7, 55.3). Other efficacy results are shown in the table below. The most common adverse events (AEs [all grades], ≥60% of patients), suspected to be drug related, were diarrhea (83.1%), nausea (76.6%), and vomiting (69.4%). Grade 3/4 AEs suspected to be drug related were reported in 81 patients (65.3%). Overall, 18 patients (14.5%) had an AE leading to treatment discontinuation.
| Investigator Assessment (N* = 124) | BIRC Assessment (N* = 124) | |
| Overall response rate, n (%) (95% CI) | 84 (67.7) (58.8, 75.9) | 79 (63.7) (54.6, 72.2) |
| Disease control rate, n (%) (95% CI) | 112 (90.3) (83.7, 94.9) | 107 (86.3) (79.0, 91.8) |
|
Median duration of response (in responders), months (95% CI) | M‡ = 84 24.0 (14.8, 37.5) | M‡ = 79 27.3 (16.6, 44.3) |
| Median progression-free survival, months (95% CI) | 16.6 (11.0, 23.2) | 19.4 (10.9, 29.3) |
| *Total number of patients included in the full analysis set. ‡Total number of patients with confirmed complete response or partial response. | ||
Conclusions
Ceritinib demonstrated prolonged and clinically meaningful OS, PFS, and DOR in chemotherapy pretreated (≤3 lines), ALKi-naïve patients with ALK+ NSCLC. The safety profile is consistent with the previous studies.
Clinical trial identification
NCT01685138
Editorial Acknowledgement
Resources from the same session
2521 - Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase 3 ALTA-1L trial
Presenter: Sanjay Popat
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
5074 - Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study
Presenter: Rafal Dziadziuszko
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
4315 - Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
Presenter: Benjamin Solomon
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
1727 - Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC ASCEND-8)
Presenter: Byoung Chul Cho
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
Poster Discussion session - NSCLC, metastatic 1 - Invited Discussant LBA57, LBA58, 1379PD, 1380PD and LBA59
Presenter: Pasi Janne
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Slides
Webcast
1458 - Uncommon EGFR mutations in lung adenocarcinomas: clinical features and response to tyrosine kinase inhibitors
Presenter: Aurélien Brindel
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
1404 - Gefitinib With or Without Pemetrexed in Nonsquamous (NS) Non–Small Cell Lung Cancer (NSCLC) With EGFR Mutation (mut): Final Overall Survival (OS) Results From a Randomized Phase II Study
Presenter: James Chih-Hsin Yang
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
2191 - Phase III Study of Gefitinib (G) versus Gefitinib+Carboplatin+Pemetrexed (GCP) as 1st-line Treatment for Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations (NEJ009)
Presenter: Masahiro Seike
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
4823 - An open-label, multicenter, phase 1 study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)
Presenter: Ross Camidge
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
2111 - Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Daniel Shao Weng Tan
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract